
Resources Available for Patients with HIV Drug Resistance
The panel concludes its discussion by talking about resources available for providers in managing their patients with HIV who experience drug resistance.
Episodes in this series

BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following question:
- When resistance occurs, what resources can health care providers use to help patients in their treatment journey?
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.